Arsenic Trioxide for Structural p53 Mutations

Status Recruiting

Clinical Trial Summary

TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with thermostability and transcriptional activity. Under Vivo and Vitro experiments, arsenic trioxide could reactivate mutated p53 to inhibit tumor. This trial aimed to explore the efficacy and safety of arsenic trioxide in refractory cancer patients with structural p53 mutations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04695223
Study type	Interventional
Source	Shanghai Changzheng Hospital
Contact
Status	Recruiting
Phase	Phase 2
Start date	January 1, 2021
Completion date	October 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03336931` - PRecISion Medicine for Children With Cancer
Completed	`NCT00530192` - Molecular Profiling Protocol (SCRI-CA-001)	Phase 0
Recruiting	`NCT05852717` - Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma	Phase 2
Recruiting	`NCT06229340` - Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations	Phase 2
Completed	`NCT00551850` - A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients	Phase 1
Recruiting	`NCT06104488` - A Study of Avutometinib for People With Solid Tumor Cancers	Phase 1
Terminated	`NCT04092179` - Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers	Phase 1/Phase 2
Recruiting	`NCT06184035` - A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer	Phase 1/Phase 2
Recruiting	`NCT06024603` - Individualized Treatments in Adults With Relapsed/Refractory Cancers	N/A
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Recruiting	`NCT05864144` - A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03187288` - Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS	Phase 1
Terminated	`NCT01320280` - BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer	Phase 2
Completed	`NCT03441100` - TCR-engineered T Cells in Solid Tumors: IMA202-101	Phase 1
Recruiting	`NCT05359445` - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors	Phase 1
Recruiting	`NCT03686124` - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors	Phase 1
Recruiting	`NCT04337580` - Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer	Phase 2
Active, not recruiting	`NCT04310345` - Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents	N/A
Recruiting	`NCT05669430` - A Study of GV20-0251 in Patients With Solid Tumor Malignancies	Phase 1
Not yet recruiting	`NCT06208657` - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Phase 1/Phase 2